

Influenzavirus B Infections Drug pipeline Report 2020-Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Preclinical and Clinical Drugs

https://marketpublishers.com/r/I6413EEA9E28EN.html

Date: October 2019

Pages: 100

Price: US\$ 1,699.00 (Single User License)

ID: I6413EEA9E28EN

Abstracts

Influenzavirus B Infections Drug pipeline report- 2020 is an annual R&D review of Influenzavirus B Infections pipeline candidates. The report presents the current status of all major Influenzavirus B Infections therapeutic compounds. Detailed insights into Influenzavirus B Infections pipeline development, current status, companies, drug profiles and Influenzavirus B Infections preclinical and clinical trials are included.

2020 Influenzavirus B Infections Pipeline Market Insights
Influenzavirus B Infections disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Influenzavirus B Infections therapies, pipeline by phase and others are included.

Influenzavirus B Infections pipeline Drug profiles-

Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Influenzavirus B Infections Therapeutic Drug candidates
Both active and inactive Influenzavirus B Infections pipeline drug candidates are
included in the report

Influenzavirus B Infections Clinical Trials and preclinical Studies
Influenzavirus B Infections In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other



details are provided.

Influenzavirus B Infections pipeline market developments
Influenzavirus B Infections Pipeline market news and deals including mergers,
acquisitions, approvals, collaborations, trial initiations, results, investments, licensing
opportunities and others are provided.

Influenzavirus B Infections pipeline companies in active development
The report analyzes Influenzavirus B Infections pipeline of the below companies-

AbbVie Inc, Adimmune Corp, Altravax Inc, Amarillo Biosciences Inc, Aphios Corp, AstraZeneca Plc, AusBio Ltd, Biotron Ltd, Cocrystal Pharma Inc, ContraFect Corp, Daiichi Sankyo Co Ltd, Evotec AG, GC Pharma, GlaxoSmithKline Plc, Inovio Pharmaceuticals Inc, iQur Ltd, Medicago Inc, MedImmune LLC, Novavax Inc, Romark Laboratories LC, Sanofi, Seqirus Ltd, Shionogi & Co Ltd, SK Bioscience, Vacthera BioTech GmbH, Vaxart Inc, Viramatix Sdn Bhd

Report Coverage

What to look out for in 2020

Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

Pipeline Snapshot

Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

Companies

27 Companies investing in Influenzavirus B Infections pipeline from discovery stage to pre-registration phase are included

Drug profiles

Over 10 details of each Influenzavirus B Infections pipeline candidate are included

Company Profiles

Business overview and contact details of all companies operating in the industry are provided

Market Developments



News, Developments and other recent industry developments are included



Contents

1. INFLUENZAVIRUS B INFECTIONS PIPELINE MARKET INSIGHTS, 2020

- 1.1 Influenzavirus B Infections Disease Overview
- 1.2 Influenzavirus B Infections Drug Pipeline Snapshot, 2020
 - 1.2.1 Influenzavirus B Infections Pipeline Drugs by Phase
 - 1.2.2 Influenzavirus B Infections Pipeline Drugs by Company
- 1.2.3 Influenzavirus B Infections Pipeline Drugs by Mechanism of Action
- 1.2.4 Influenzavirus B Infections Pipeline Drugs by Route of Administration

2. INFLUENZAVIRUS B INFECTIONS COMPANY WISE PIPELINE DETAILS

AbbVie Inc Influenzavirus B Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Adimmune Corp Influenzavirus B Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Altravax Inc Influenzavirus B Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Amarillo Biosciences Inc Influenzavirus B Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Aphios Corp Influenzavirus B Infections Pipeline Drugs

Company Profile

Drug Candidate Details

AstraZeneca Plc Influenzavirus B Infections Pipeline Drugs

Company Profile

Drug Candidate Details

AusBio Ltd Influenzavirus B Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Biotron Ltd Influenzavirus B Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Cocrystal Pharma Inc Influenzavirus B Infections Pipeline Drugs

Company Profile



Drug Candidate Details

ContraFect Corp Influenzavirus B Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Daiichi Sankyo Co Ltd Influenzavirus B Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Evotec AG Influenzavirus B Infections Pipeline Drugs

Company Profile

Drug Candidate Details

GC Pharma Influenzavirus B Infections Pipeline Drugs

Company Profile

Drug Candidate Details

GlaxoSmithKline Plc Influenzavirus B Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Inovio Pharmaceuticals Inc Influenzavirus B Infections Pipeline Drugs

Company Profile

Drug Candidate Details

iQur Ltd Influenzavirus B Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Medicago Inc Influenzavirus B Infections Pipeline Drugs

Company Profile

Drug Candidate Details

MedImmune LLC Influenzavirus B Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Novavax Inc Influenzavirus B Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Romark Laboratories LC Influenzavirus B Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Sanofi Influenzavirus B Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Segirus Ltd Influenzavirus B Infections Pipeline Drugs

Company Profile



Drug Candidate Details

Shionogi & Co Ltd Influenzavirus B Infections Pipeline Drugs

Company Profile

Drug Candidate Details

SK Bioscience Influenzavirus B Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Vacthera BioTech GmbH Influenzavirus B Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Vaxart Inc Influenzavirus B Infections Pipeline Drugs

Company Profile

Drug Candidate Details

Viramatix Sdn Bhd Influenzavirus B Infections Pipeline Drugs

Company Profile

Drug Candidate Details

3. INFLUENZAVIRUS B INFECTIONS DRUG PIPELINE PROFILES

- 3.1 Discovery and Preclinical Drug Profiles
- 3.2 Phase 1 Drug Profiles
- 3.3 Phase 2 Drug Profiles
- 3.4 Phase 3 Drug Profiles

4. INFLUENZAVIRUS B INFECTIONS PIPELINE NEWS AND DEVELOPMENTS

5. APPENDIX

- 5.1 Primary and Secondary Research Methodology
- 5.2 Publisher Expertize
- 5.3 Contacts



I would like to order

Product name: Influenzavirus B Infections Drug pipeline Report 2020- Current Status, Phase,

Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and

Clinical Drugs

Product link: https://marketpublishers.com/r/l6413EEA9E28EN.html

Price: US\$ 1,699.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/l6413EEA9E28EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

| First name: | |
|---------------|---------------------------|
| Last name: | |
| Email: | |
| Company: | |
| Address: | |
| City: | |
| Zip code: | |
| Country: | |
| Tel: | |
| Fax: | |
| Your message: | |
| | |
| | |
| | |
| | **All fields are required |
| | Custumer signature |
| | |
| | |

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970